Abstract:1089 Background: The addition of bevacizumab (B) to paclitaxel (P) results in a significant improvement in PFS in pts with metastatic breast cancer (MBC) (Miller K, et al. New Engl J Med 2007). A randomized Phase II trial examining the efficacy and safety of adding gemcitabine (G) to the PB doublet has completed enrollment. Reported here are preliminary efficacy and safety results. Methods: This is a US, multicenter, randomized, superiority trial. Eligible pts have locally advanced or metastatic breast cancer… Show more
“…PB is used to treat metastatic breast cancer ( Table 1 ). 1-10 PB has also been used in other advanced cancers such as ovarian, lung, and melanoma. 11-13…”
Section: Indicationsmentioning
confidence: 99%
“…Because febrile neutropenia was reported in 0.3% to 8% of patients in the trials reviewed, 3-5,7,8 prophylactic use of colony stimulating factors is not recommended. Colony stimulating factors may be considered if a patient experiences febrile neutropenia or grade 4 neutropenia.…”
Section: Supportive Carementioning
confidence: 99%
“…Cardiovascular: Epistaxis (grade 3 or 4) 1% to 4% 3,6-8,10 ; hypertension (grade 1) 7%, 4 (grade 3) 1% to 17%, 3,8,10,11 (grade 4) 0.5% 3,8 ; thrombus (grade 2) 3% to 4%, 4 (grade 3) 2% to 4%, 3,8 (grade 4) 1% to 4%., 3,7,8…”
Section: Major Toxicitiesmentioning
confidence: 99%
“…Hematologic: Neutropenia (grade 3) 3% to 33%, 4-9 (grade 4) 2% to 8% 4-9,11,12 ; febrile neutropenia 0.3% to 8% 3-5,7,8 ; anemia (grade 1 or 2) 2% to 7%, 3,4,6-8,11,12 (grade 3) 2% to 4%. 3,6-8,11…”
Section: Major Toxicitiesmentioning
confidence: 99%
“…Renal Function Paclitaxel: No dosage reduction necessary for renal function 19 Bevacizumab Bevacizumab should be held for 2+ or greater on dipstick urine analysis until resolution 2 If 24-hour urine protein collection shows greater than or equal to 2 g protein/24 hours, bevacizumab should be held until urine protein is less than 2 g protein/24 hours 2 In the studies reviewed, bevacizumab was held for grade 2 or 3 proteinuria until resolution. 3-13 …”
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
“…PB is used to treat metastatic breast cancer ( Table 1 ). 1-10 PB has also been used in other advanced cancers such as ovarian, lung, and melanoma. 11-13…”
Section: Indicationsmentioning
confidence: 99%
“…Because febrile neutropenia was reported in 0.3% to 8% of patients in the trials reviewed, 3-5,7,8 prophylactic use of colony stimulating factors is not recommended. Colony stimulating factors may be considered if a patient experiences febrile neutropenia or grade 4 neutropenia.…”
Section: Supportive Carementioning
confidence: 99%
“…Cardiovascular: Epistaxis (grade 3 or 4) 1% to 4% 3,6-8,10 ; hypertension (grade 1) 7%, 4 (grade 3) 1% to 17%, 3,8,10,11 (grade 4) 0.5% 3,8 ; thrombus (grade 2) 3% to 4%, 4 (grade 3) 2% to 4%, 3,8 (grade 4) 1% to 4%., 3,7,8…”
Section: Major Toxicitiesmentioning
confidence: 99%
“…Hematologic: Neutropenia (grade 3) 3% to 33%, 4-9 (grade 4) 2% to 8% 4-9,11,12 ; febrile neutropenia 0.3% to 8% 3-5,7,8 ; anemia (grade 1 or 2) 2% to 7%, 3,4,6-8,11,12 (grade 3) 2% to 4%. 3,6-8,11…”
Section: Major Toxicitiesmentioning
confidence: 99%
“…Renal Function Paclitaxel: No dosage reduction necessary for renal function 19 Bevacizumab Bevacizumab should be held for 2+ or greater on dipstick urine analysis until resolution 2 If 24-hour urine protein collection shows greater than or equal to 2 g protein/24 hours, bevacizumab should be held until urine protein is less than 2 g protein/24 hours 2 In the studies reviewed, bevacizumab was held for grade 2 or 3 proteinuria until resolution. 3-13 …”
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.